EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Probiotic treatment with viable α‐galactosylceramide ‐producing Bacteroides fragilis reduces diabetes incidence in female nonobese diabetic mice

Camilla H F Hansen iD, Danica Jozipovic iD, Line F Zachariassen, Dennis S Nielsen, Axel K Hansen, Karsten Buschard iD

Journal of Diabetes · 2024-08 · 16 (8)

DOI: 10.1111/1753-0407.13593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes, online erschienen am 13.08.2024. Verfasst von Camilla H F Hansen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C, Denmark. Hauptthemen laut MEDLINE: Bacteroides fragilis, Mice, Inbred NOD, Galactosylceramides, Probiotics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Rigmor Morans Mindefond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to investigate whether alpha‐galactosylceramide (α‐GalCer)‐producing Bacteroides fragilis could induce natural killer T (NKT) cells in nonobese diabetic (NOD) mice and reduce their diabetes incidence.

Methods

Five‐week‐old female NOD mice were treated orally with B. fragilis , and islet pathology and diabetes onset were monitored. Immune responses were analyzed by flow cytometry and multiplex technology. Effects of ultraviolet (UV)‐killed α‐GalCer‐producing B. fragilis and their culture medium on invariant NKT (iNKT) cells were tested ex vivo on murine splenocytes, and the immunosuppressive capacity of splenocytes from B. fragilis ‐treated NOD mice were tested by adoptive transfer to nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice.

Results

B. fragilis reduced the diabetes incidence from 69% to 33% and the percent of islets with insulitis from 40% to 7%, which doubled the serum insulin level compared with the vehicle‐treated control mice. Furthermore, the early treatment reduced proinflammatory mediators in the serum, whereas the proportion of CD4 + NKT cell population was increased by 33%. B. fragilis growth media stimulated iNKT cells and anti‐inflammatory M2 macrophages ex vivo in contrast to UV‐killed bacteria, which had no effect, strongly indicating an α‐GalCer‐mediated effect. Adoptive transfer of splenocytes from B. fragilis ‐treated NOD mice induced a similar diabetes incidence as splenocytes from untreated NOD mice.

Conclusions

B. fragilis induced iNKT cells and M2 macrophages and reduced type 1 diabetes in NOD mice. The protective effect seemed to be more centered on gut–pancreas interactions rather than a systemic immunosuppression. B. fragilis should be considered for probiotic use in individuals at risk of developing type 1 diabetes. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bacteroides fragilisMice, Inbred NODGalactosylceramidesProbioticsNatural Killer T-CellsAnimalsFemaleMiceDiabetes Mellitus, Type 1IncidenceMice, SCID

Stichwörter der Autor:innen

Bacteroides fragilisM2 macrophagesNKT cellsalpha‐galactosylceramidegut barriertype 1 diabetes

Substanzen

Galactosylceramidesalpha-galactosylceramide

Autor:innen und Institutionen

  • Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C, Denmark.
  • Department of Food Science, Faculty of Science, University of Copenhagen, Frederiksberg C, Denmark.
  • Department of Pathology, The Bartholin Institute, Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Camilla H F Hansen, Danica Jozipovic, Karsten Buschard

Förderung

  • Sigrid Rigmor Morans Mindefond

Zitieren

APA

Hansen, C. H. F., Jozipovic, D., Zachariassen, L. F., Nielsen, D. S., Hansen, A. K., & Buschard, K. (2024). Probiotic treatment with viable α‐galactosylceramide ‐producing Bacteroides fragilis reduces diabetes incidence in female nonobese diabetic mice. Journal of Diabetes, 16(8). https://doi.org/10.1111/1753-0407.13593

Vancouver

Hansen CHF, Jozipovic D, Zachariassen LF, Nielsen DS, Hansen AK, Buschard K. Probiotic treatment with viable α‐galactosylceramide ‐producing Bacteroides fragilis reduces diabetes incidence in female nonobese diabetic mice. Journal of Diabetes. 2024;16(8). doi:10.1111/1753-0407.13593

BibTeX
@article{Hansen2024,
  author = {Hansen, Camilla H F and Jozipovic, Danica and Zachariassen, Line F and Nielsen, Dennis S and Hansen, Axel K and Buschard, Karsten},
  title = {Probiotic treatment with viable α‐galactosylceramide ‐producing Bacteroides fragilis reduces diabetes incidence in female nonobese diabetic mice},
  journal = {Journal of Diabetes},
  year = {2024},
  volume = {16},
  number = {8},
  doi = {10.1111/1753-0407.13593}
}
Kostenlos starten →